---
layout: post
title: "港A医药板块逆势走强！券商看好CXO行情：估值历史低位 催化不断（附名单）"
date: 2022-02-14 15:30:42 +0800
categories: emnews
tags: 东财滚动新闻
---
> 港A医药板块逆势走强！券商看好CXO行情：估值历史低位，催化不断（附名单）。

<p>周一港A两地CXO板块集体走强，A股<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>涨停，<span id="Info.116.03347"><a href="http://quote.eastmoney.com/unify/r/116.03347" class="keytip" data-code="116,03347">泰格医药</a></span>(<span id="Info.3316"><a href="http://data.eastmoney.com/hsgt/index.html" class="infokey">深股通</a></span>)涨超5%，<span id="Info.116.06821"><a href="http://quote.eastmoney.com/unify/r/116.06821" class="keytip" data-code="116,06821">凯莱英</a></span>(深股通)涨近5%，<span id="stock_1.688202"><a href="http://quote.eastmoney.com/unify/r/1.688202" class="keytip" data-code="1,688202">美迪西</a></span><span id="quote_1.688202"></span>涨超4%，<span id="Info.116.03759"><a href="http://quote.eastmoney.com/unify/r/116.03759" class="keytip" data-code="116,03759">康龙化成</a></span>(深股通)涨超3%，<span id="Info.116.02359"><a href="http://quote.eastmoney.com/unify/r/116.02359" class="keytip" data-code="116,02359">药明康德</a></span>(<span id="Info.3315"><a href="http://data.eastmoney.com/hsgt/index.html" class="infokey">沪股通</a></span>)涨近4%；港股<span id="Info.116.01672"><a href="http://quote.eastmoney.com/unify/r/116.01672" class="keytip" data-code="116,01672">歌礼制药-B</a></span>大涨近13%，金斯瑞涨超6%，<span web="1" href="http://quote.eastmoney.com/unify/r/116.03347" class="em_stock_key_common" data-code="116,03347">泰格医药</span>涨超4%，<span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>、<span id="Info.116.06127"><a href="http://quote.eastmoney.com/unify/r/116.06127" class="keytip" data-code="116,06127">昭衍新药</a></span>涨超2%，<span id="Info.116.02269"><a href="http://quote.eastmoney.com/unify/r/116.02269" class="keytip" data-code="116,02269">药明生物</a></span>和<span web="1" href="http://quote.eastmoney.com/unify/r/116.03759" class="em_stock_key_common" data-code="116,03759">康龙化成</span>涨近1%。</p><p>消息面上，2月12日CDE官网公布附条件批准<span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装(即Paxlovid)进口注册。进行新冠治疗药物及CDMO供应链持续迎来重磅利好。</p><p>此外，2月13日<span web="1" href="http://quote.eastmoney.com/unify/r/116.03347" class="em_stock_key_common" data-code="116,03347">泰格医药</span><span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>将以不高于120.00元/股<span id="Info.3285"><a href="http://data.eastmoney.com/gphg/" class="infokey">回购</a></span>2.5亿-5亿公司股票，用于后期实施A股股权激励计划或A股员工持股计划。</p><p>行业基本面方面，<strong>CXO企业2021年<span id="Info.3324"><a href="http://data.eastmoney.com/bbsj/" class="infokey">净利润</a></span>维持高增长，行业景气度仍高。</strong></p><p>CXO企业于近期陆续披露2021年<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>预告，市场较为关注的头部企业<span web="1" href="http://quote.eastmoney.com/unify/r/116.02269" class="em_stock_key_common" data-code="116,02269">药明生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.03759" class="em_stock_key_common" data-code="116,03759">康龙化成</span>、泰格、<span web="1" href="http://quote.eastmoney.com/unify/r/116.06821" class="em_stock_key_common" data-code="116,06821">凯莱英</span>和<span web="1" href="http://quote.eastmoney.com/unify/r/116.06127" class="em_stock_key_common" data-code="116,06127">昭衍新药</span>预计归母净利润均维持较高同比增速。</p><p>6家CXO企业净利润平均增速为65%，净利润增速相对更低的<span web="1" href="http://quote.eastmoney.com/unify/r/116.06821" class="em_stock_key_common" data-code="116,06821">凯莱英</span>扣非归母净利预计同比也有41-46%的高速增长；已披露的收入增速也基本在40%左右甚至更高。</p><p>浦银国际表示，这反映<strong>了CXO行业景气度仍处于高位、订单充足，头部CXO企业产能释放后能很快承接订单、产生收入，并转化为高速的业绩增长</strong>。</p><p><span id="stock_1.601555"><a href="http://quote.eastmoney.com/unify/r/1.601555" class="keytip" data-code="1,601555">东吴证券</a></span><span id="quote_1.601555"></span>最新<span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span>称，2022年国内主流CXO公司平均市盈率为41倍，PEG均值0.93，<strong>与国外CXO公司相比，A股CXO估值已经大幅消化。</strong></p><p>回顾2021年全球及中国药企研发投入、新药管线数量、医疗健康产业融资额与融资数，<strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.601555" class="em_stock_key_common" data-code="1,601555">东吴证券</span>认为CXO需求不减，仍具备充足动能。国内CXO公司2021年业绩预告也展现出CXO业绩能见度从未改变，<span web="1" href="http://quote.eastmoney.com/unify/r/1.601555" class="em_stock_key_common" data-code="1,601555">东吴证券</span>认为具备配备价值。</strong></p><p><span id="stock_1.601878"><a href="http://quote.eastmoney.com/unify/r/1.601878" class="keytip" data-code="1,601878">浙商证券</a></span><span id="quote_1.601878"></span>分析，<strong>2021-2022年CXO板块受政策(医保谈判、CDE、贸易冲突)和投融资影响迎来历史估值底部，外部催化不断，内部经营质量和海外大客户认可度持续提升前景下，看好CXO行情。</strong></p><p><strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.601878" class="em_stock_key_common" data-code="1,601878">浙商证券</span>重点推荐</strong>：有望持续受益<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>新冠治疗药物CDMO产业链的<strong><span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>、<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span></strong>、<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span></strong>等。估值底部积极进行回购的临床CRO龙头<strong><span id="stock_0.300347"><a href="http://quote.eastmoney.com/unify/r/0.300347" class="keytip" data-code="0,300347">泰格医药</a></span><span id="quote_0.300347"></span></strong>。估值性价比较高CXO龙头<strong><span web="1" href="http://quote.eastmoney.com/unify/r/116.06127" class="em_stock_key_common" data-code="116,06127">昭衍新药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688202" class="em_stock_key_common" data-code="1,688202">美迪西</span>、<span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span>、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span></strong>等。</p><p><strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.601878" class="em_stock_key_common" data-code="1,601878">浙商证券</span>建议重点关注：</strong>自主可控新冠治疗药物创新药企业<strong>君</strong><strong>实生物、<span id="stock_0.002317"><a href="http://quote.eastmoney.com/unify/r/0.002317" class="keytip" data-code="0,002317">众生药业</a></span><span id="quote_0.002317"></span>、<span id="stock_0.300436"><a href="http://quote.eastmoney.com/unify/r/0.300436" class="keytip" data-code="0,300436">广生堂</a></span><span id="quote_0.300436"></span>、歌礼制药</strong>等，关注<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>新冠治疗方向的<strong><span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span></strong>等。</p><p><strong>德邦<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>发研报指，在全市场及<span web="1" href="http://quote.eastmoney.com/unify/r/116.02269" class="em_stock_key_common" data-code="116,02269">药明生物</span>受美国UVL 名单的影响下，市场对医药板块的负面情绪在节后的一周释放充分，</strong>当前医药板块下跌受市场负面情绪单方面影响，与行业基本面基本无关。</p><p><strong>德邦<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>认为，医药板块的</strong><strong>急速下跌给予极佳的布局机会</strong>：</p><p><strong>1)新冠治疗药物将成未来重大投资板块</strong>：国家药监局近日批准<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>新冠特效药Paxlovid 在国内紧急使用，国门开放预期提前，新冠治疗药物市场有望达到千亿级别，是继新冠疫苗与新冠检测后的最重要投资板块，且持续性远超疫苗与检测，“中西结合”将是国内新冠治疗的主流方式，重点关注新冠小分子与产业链+抗新冠<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>板块，重点关注：<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>、<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span>、<span id="stock_1.603858"><a href="http://quote.eastmoney.com/unify/r/1.603858" class="keytip" data-code="1,603858">步长制药</a></span><span id="quote_1.603858"></span></strong>等；</p><p><strong>2)CXO行业回调充分</strong>：国内CXO 企业早已度过简单加工制造时代，已具备全球核心竞争力，欧美药企离不开中国的低成本与高效率的CXO 产能，全球产能需求持续往中国转移。推荐重点关注：<strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、药明生物、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>、博腾股份、<span id="stock_0.300759"><a href="http://quote.eastmoney.com/unify/r/0.300759" class="keytip" data-code="0,300759">康龙化成</a></span><span id="quote_0.300759"></span></strong>等；</p><p><strong>3)</strong><strong><span id="bk_90.BK1044"><a href="http://quote.eastmoney.com/unify/r/90.BK1044" class="keytip" data-code="90,BK1044">生物制品</a></span><span id="bkquote_90.BK1044"></span>上游板块迎来重大机遇</strong>：药明生物事件突出了国内生物药上游供应链安全问题，上游国产替代是大势所趋。供应链上来看，国内<span id="stock_0.300171"><a href="http://quote.eastmoney.com/unify/r/0.300171" class="keytip" data-code="0,300171">东富龙</a></span><span id="quote_0.300171"></span>、<span id="stock_0.300358"><a href="http://quote.eastmoney.com/unify/r/0.300358" class="keytip" data-code="0,300358">楚天科技</a></span><span id="quote_0.300358"></span>、<span id="Info.116.02155"><a href="http://quote.eastmoney.com/unify/r/116.02155" class="keytip" data-code="116,02155">森松国际</a></span>、多宁生物、<span id="stock_1.688690"><a href="http://quote.eastmoney.com/unify/r/1.688690" class="keytip" data-code="1,688690">纳微科技</a></span><span id="quote_1.688690"></span>、科百特、奥浦迈等企业在不同的设备及耗材领域均有突破，极端情况下，国内企业基本具备完整供应的能力。建议关注<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.300171" class="em_stock_key_common" data-code="0,300171">东富龙</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300358" class="em_stock_key_common" data-code="0,300358">楚天科技</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.02155" class="em_stock_key_common" data-code="116,02155">森松国际</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688690" class="em_stock_key_common" data-code="1,688690">纳微科技</span></strong>等。</p><p><strong>4)</strong><strong>持续看好<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>板块：</strong>中药景气行情有望贯穿全年，本轮急跌给予重新布局机会：德邦<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>认为，中医药已经上升为国家战略高度，作为国家文化与软实力的有效承载，国家为中医药的传承创新单独立法，各部门特别是医保局也单独发文从支付端支持，对中药的支持大概率能体现在公司收入和利润增速上。低估值+政策大力支持是未来中药行情持续向上的重要基础，重点关注中药创新、配方颗粒、抗新冠中药等方向相关标的：<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603858" class="em_stock_key_common" data-code="1,603858">步长制药</span>、<span id="stock_1.600129"><a href="http://quote.eastmoney.com/unify/r/1.600129" class="keytip" data-code="1,600129">太极集团</a></span><span id="quote_1.600129"></span>、<span id="Info.116.00570"><a href="http://quote.eastmoney.com/unify/r/116.00570" class="keytip" data-code="116,00570">中国中药</a></span>、<span id="stock_1.600085"><a href="http://quote.eastmoney.com/unify/r/1.600085" class="keytip" data-code="1,600085">同仁堂</a></span><span id="quote_1.600085"></span>、<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>、<span id="stock_0.300026"><a href="http://quote.eastmoney.com/unify/r/0.300026" class="keytip" data-code="0,300026">红日药业</a></span><span id="quote_0.300026"></span>、<span id="stock_0.002873"><a href="http://quote.eastmoney.com/unify/r/0.002873" class="keytip" data-code="0,002873">新天药业</a></span><span id="quote_0.002873"></span></strong>等。</p><p>德邦证券本周投资组合：建议关注<strong>博腾股份、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600129" class="em_stock_key_common" data-code="1,600129">太极集团</span>、以岭药业、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002873" class="em_stock_key_common" data-code="0,002873">新天药业</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span></strong>和<strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.603858" class="em_stock_key_common" data-code="1,603858">步长制药</span></strong>等；本月投资组合：建议关注<strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span id="stock_0.300760"><a href="http://quote.eastmoney.com/unify/r/0.300760" class="keytip" data-code="0,300760">迈瑞医疗</a></span><span id="quote_0.300760"></span>、<span id="stock_0.300705"><a href="http://quote.eastmoney.com/unify/r/0.300705" class="keytip" data-code="0,300705">九典制药</a></span><span id="quote_0.300705"></span>、<span id="stock_0.002223"><a href="http://quote.eastmoney.com/unify/r/0.002223" class="keytip" data-code="0,002223">鱼跃医疗</a></span><span id="quote_0.002223"></span>、<span id="stock_1.603987"><a href="http://quote.eastmoney.com/unify/r/1.603987" class="keytip" data-code="1,603987">康德莱</a></span><span id="quote_1.603987"></span></strong>和<strong><span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span></strong>。</p><center><img src="https://dfscdn.dfcfw.com/download/D25082339324852424918_w878h1760.jpg" width="580" emheight="1163" orginial_src="https://dfscdn.dfcfw.com/download/D25082339324852424918_w878h1760_o.jpg" style="border:1px solid #d1d1d1;padding:3px;margin:5px 0px;" height="1163" /></center><center><img src="https://dfscdn.dfcfw.com/download/D25339150065577043775_w878h1760.jpg" width="580" emheight="1163" orginial_src="https://dfscdn.dfcfw.com/download/D25339150065577043775_w878h1760_o.jpg" style="border:1px solid #d1d1d1;padding:3px;margin:5px 0px;" height="1163" /></center><p><strong>相关阅读：</strong></p><p><strong><a href="https://hk.eastmoney.com/a/202202142275455974.html">浙商证券：估值历史低位 催化不断 看好CXO行情（附名单）</a><br /></strong></p><p><strong><a href="https://hk.eastmoney.com/a/202202142275439948.html">一图概览｜CXO企业2021年业绩维持高增速</a><br /></strong></p><p><strong><a href="https://stock.eastmoney.com/a/202202142275553293.html">医药行业周报：悲观情绪带来极佳机会 关注上游及新冠治疗药领域</a><br /></strong></p><p class="em_media">（文章来源：哈富资讯）</p>

<http://hk.eastmoney.com/news/11382,202202142275746048.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)